Kiora Pharmaceuticals, Inc. $KPRX Shares Sold by AIGH Capital Management LLC

AIGH Capital Management LLC decreased its position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 14.7% during the 2nd quarter, Holdings Channel.com reports. The fund owned 216,345 shares of the company’s stock after selling 37,210 shares during the period. AIGH Capital Management LLC owned 0.07% of Kiora Pharmaceuticals worth $623,000 at the end of the most recent quarter.

Kiora Pharmaceuticals Price Performance

KPRX stock opened at $2.71 on Monday. The firm has a market capitalization of $9.30 million, a P/E ratio of -0.93 and a beta of -0.67. The business’s 50-day moving average is $2.69 and its two-hundred day moving average is $2.88. Kiora Pharmaceuticals, Inc. has a 1 year low of $2.25 and a 1 year high of $4.18.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. The company had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.75 million. On average, analysts expect that Kiora Pharmaceuticals, Inc. will post 1.28 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on KPRX shares. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Kiora Pharmaceuticals in a research note on Tuesday, September 2nd. Zacks Research lowered Kiora Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kiora Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Kiora Pharmaceuticals Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.